|
|
 Previous Article | Table of Contents | Next Article 
Effect of Campath-1H antibody on human hematopoietic progenitors in vitro
MH Gilleece and TM Dexter
Department of Experimental Haematology, CRC Paterson Institute for Cancer
Research, Withington, Manchester, England.
The humanized antibody CAMPATH-1H has been shown in pilot studies to be
beneficial in the treatment of lymphoid malignancy and other
lymphoproliferative diseases. The antigen recognized by this antibody is
not confined to lymphoid cells, and work with rat antibodies of similar
specificity has not eliminated the possibility of damage to human
hematopoietic progenitors, particularly those capable of repopulating bone
marrow and sustaining hematopoiesis. This study aimed to discover if
hematopoietic progenitor cells were affected by treatment with CAMPATH-1H,
with or without human complement. Bone marrow mononuclear cells from
healthy volunteers were treated with saturating concentrations of
CAMPATH-1H, human complement, or CAMPATH- 1H plus human complement. The
CD34-positive fraction of the mononuclear cells was treated similarly.
Residual progenitor activity was measured in the colony-forming
unit-granulocyte, erythroid, monocyte, megakaryocyte assay and compared
with untreated controls. There was no significant difference (at the 5%
level) between treated and control cells. Mononuclear cells were divided
into CAMPATH-1H-positive and CAMPATH-1H-negative fractions by fluorescein
isothiocyanate-CAMPATH-1H labeling and fluorescence-activated cell sorter
separation. Hematopoietic progenitors were predominantly found in the
CAMPATH-1H- negative fraction. Furthermore, mononuclear cells treated with
CAMPATH- 1H and complement were equivalent to controls in experiments that
investigated the capacity of these cells to form hematopoietic foci in
long-term cultures.
Volume 82,
Issue 3,
pp. 807-812,
08/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. R. Ambrose, A.-S. Morel, and A. N. Warrens
Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab
Blood,
October 1, 2009;
114(14):
3052 - 3055.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Agostinelli, P P Piccaluga, P Went, M Rossi, A Gazzola, S Righi, T Sista, C Campidelli, P L Zinzani, B Falini, et al.
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies
J. Clin. Pathol.,
November 1, 2008;
61(11):
1160 - 1167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Lapalombella, X. Zhao, G. Triantafillou, B. Yu, Y. Jin, G. Lozanski, C. Cheney, N. Heerema, D. Jarjoura, A. Lehman, et al.
A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
Clin. Cancer Res.,
January 15, 2008;
14(2):
569 - 578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hillmen, A. B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, and J. Mayer
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
December 10, 2007;
25(35):
5616 - 5623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Piccaluga, C. Agostinelli, S. Righi, P. L. Zinzani, and S. A. Pileri
Expression of CD52 in peripheral T-cell lymphoma
Haematologica,
April 1, 2007;
92(4):
566 - 567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Montillo, A. Tedeschi, S. Miqueleiz, S. Veronese, R. Cairoli, L. Intropido, F. Ricci, A. Colosimo, B. Scarpati, M. Montagna, et al.
Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 20, 2006;
24(15):
2337 - 2342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moreton, B. Kennedy, G. Lucas, M. Leach, S. M.B. Rassam, A. Haynes, J. Tighe, D. Oscier, C. Fegan, A. Rawstron, et al.
Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival
J. Clin. Oncol.,
May 1, 2005;
23(13):
2971 - 2979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Enblad, H. Hagberg, M. Erlanson, J. Lundin, A. P. MacDonald, R. Repp, J. Schetelig, G. Seipelt, and A. Osterborg
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
Blood,
April 15, 2004;
103(8):
2920 - 2924.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, T. K. Kimlinger, J. A. Lust, K. Donovan, and T. E. Witzig
Expression of CD52 on plasma cells in plasma cell proliferative disorders
Blood,
August 1, 2003;
102(3):
1075 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lundin, H. Hagberg, R. Repp, E. Cavallin-Stahl, S. Freden, G. Juliusson, E. Rosenblad, G. Tjonnfjord, T. Wiklund, and A. Osterborg
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
Blood,
June 1, 2003;
101(11):
4267 - 4272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-W. Li, D. Tang, K. P. Ahrens, J.-X. She, R. C. Braylan, and L. Yang
All-trans-retinoic acid induces CD52 expression in acute promyelocytic leukemia
Blood,
March 1, 2003;
101(5):
1977 - 1980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ratzinger, J. L. Reagan, G. Heller, K. J. Busam, and J. W. Young
Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation
Blood,
February 15, 2003;
101(4):
1422 - 1429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Rai, C. E. Freter, R. J. Mercier, M. R. Cooper, B. S. Mitchell, E. A. Stadtmauer, P. Santabarbara, B. Wacker, and L. Brettman
Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine
J. Clin. Oncol.,
September 15, 2002;
20(18):
3891 - 3897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lundin, E. Kimby, M. Bjorkholm, P.-A. Broliden, F. Celsing, V. Hjalmar, L. Mollgard, P. Rebello, G. Hale, H. Waldmann, et al.
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
Blood,
July 18, 2002;
100(3):
768 - 773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, I. Flinn, V. Jain, J.-L. Binet, P. Hillmen, J. Byrd, M. Albitar, L. Brettman, P. Santabarbara, B. Wacker, et al.
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Blood,
May 15, 2002;
99(10):
3554 - 3561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Dearden, E. Matutes, B. Cazin, G. E. Tjonnfjord, A. Parreira, B. Nomdedeu, P. Leoni, F. J. Clark, D. Radia, S. M. B. Rassam, et al.
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
Blood,
September 15, 2001;
98(6):
1721 - 1726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kee Shin, E. Young Choi, S. Hyung Kim, J. Chung, D. Hyun Chung, W. Seo Park, K. Cheon Jung, H. Sik Kim, S. Park, H. Jin Kim, et al.
Expression of Leukemia-Associated Antigen, JL1, in Bone Marrow and Thymus
Am. J. Pathol.,
April 1, 2001;
158(4):
1473 - 1480.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
